Andrew M. Evens, DO, MSc, FACP | Authors

Articles

Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL

December 03, 2019

Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.